Insider transactions

EDGAR

Tenax Therapeutics, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
20 transactions, 3,699,112 shares
Sum of shares × price per share: 6,496,808.8071
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–34 of 34

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-10-21 Filed 2026-10-21ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)331,9791.6588
550,686.7652

Derived: shares × price per share. Exact value 550686.7652.

7,447,000Indirect (I) See FootnoteNo
F3, F4, F5
  • F3 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.6200 to $1.6900, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F4 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F5 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000027 Read from the filing’s XML Dispute this row
2026-10-20 Filed 2026-10-21ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)254,3421.5952
405,726.3584

Derived: shares × price per share. Exact value 405726.3584.

7,115,021Indirect (I) See FootnoteNo
F2, F4, F5
  • F2 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.5000 to $1.6300, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F4 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F5 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000027 Read from the filing’s XML Dispute this row
2026-10-19 Filed 2026-10-21ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)336,5281.5066
507,013.0848

Derived: shares × price per share. Exact value 507013.0848.

6,860,679Indirect (I) See FootnoteNo
F1, F4, F5
  • F1 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.4300 to $1.5350, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F4 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F5 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000027 Read from the filing’s XML Dispute this row
2026-09-16 Filed 2026-09-17Doogan Declan Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)53,0001.92
101,760

Derived: shares × price per share. Exact value 101760.00.

55,274Direct (D) No— Open filing 0001193125-26-394831 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-15Giordano Christopher Thomas Director · Officer: CEO
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)4,8501.8221
8,837.185

Derived: shares × price per share. Exact value 8837.1850.

22,174Direct (D) No
F2
  • F2 This transaction was executed in multiple trades at prices ranging from $1.82 to $1.83. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Open filing 0001871714-26-000002 Read from the filing’s XML Dispute this row
2026-09-11 Filed 2026-09-15STAAB THOMAS R II Officer: Chief Financial Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)5,6751.935
10,981.125

Derived: shares × price per share. Exact value 10981.125.

15,675Direct (D) No
F1
  • F1 This transaction was executed in multiple trades at prices ranging from $1.90 to $1.95. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Open filing 0001193125-26-392319 Read from the filing’s XML Dispute this row
2026-09-11 Filed 2026-09-15Giordano Christopher Thomas Director · Officer: CEO
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)6,0001.875
11,250

Derived: shares × price per share. Exact value 11250.000.

17,324Direct (D) No
F1
  • F1 This transaction was executed in multiple trades at prices ranging from $1.87 to $1.88. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Open filing 0001871714-26-000002 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-08ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)900,0001.7824
1,604,160

Derived: shares × price per share. Exact value 1604160.0000.

6,524,151Indirect (I) See FootnoteNo
F1, F2, F3
  • F1 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7800 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F2 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F3 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000020 Read from the filing’s XML Dispute this row
2026-09-02 Filed 2026-09-02ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)187,7041.7985
337,585.644

Derived: shares × price per share. Exact value 337585.6440.

5,624,151Indirect (I) See FootnoteNo
F3, F4, F5
  • F3 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7750 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F4 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F5 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000019 Read from the filing’s XML Dispute this row
2026-09-01 Filed 2026-09-02ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)179,0581.7959
321,570.2622

Derived: shares × price per share. Exact value 321570.2622.

5,436,447Indirect (I) See FootnoteNo
F2, F4, F5
  • F2 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7700 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F4 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F5 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000019 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-02ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)403,5711.7905
722,593.8755

Derived: shares × price per share. Exact value 722593.8755.

5,257,389Indirect (I) See FootnoteNo
F1, F4, F5
  • F1 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7700 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F4 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F5 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000019 Read from the filing’s XML Dispute this row
2026-08-24 Filed 2026-08-24ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)107,3741.7542
188,355.4708

Derived: shares × price per share. Exact value 188355.4708.

4,853,818Indirect (I) See FootnoteNo
F3, F4, F5
  • F3 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7000 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F4 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F5 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000017 Read from the filing’s XML Dispute this row
2026-08-21 Filed 2026-08-24ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)716,3691.7676
1,266,253.8444

Derived: shares × price per share. Exact value 1266253.8444.

4,746,444Indirect (I) See FootnoteNo
F2, F4, F5
  • F2 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7250 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F4 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F5 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000017 Read from the filing’s XML Dispute this row
2026-08-20 Filed 2026-08-24ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)202,1241.7788
359,538.1712

Derived: shares × price per share. Exact value 359538.1712.

4,030,075Indirect (I) See FootnoteNo
F1, F4, F5
  • F1 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7650 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F4 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F5 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000017 Read from the filing’s XML Dispute this row
2026-07-13 Filed 2026-07-14Giordano Christopher Thomas Director · Officer: CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)2193.549
777.231

Derived: shares × price per share. Exact value 777.231.

2,824Direct (D) No
F1
  • F1 The aggregate exercise price was paid in cash.
Open filing 0001193125-26-303600 Read from the filing’s XML Dispute this row
2026-07-13 Filed 2026-07-14Giordano Christopher Thomas Director · Officer: CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)8,5005.94
50,490

Derived: shares × price per share. Exact value 50490.00.

11,324Direct (D) No
F1
  • F1 The aggregate exercise price was paid in cash.
Open filing 0001193125-26-303600 Read from the filing’s XML Dispute this row
2026-07-13 Filed 2026-07-14Giordano Christopher Thomas Director · Officer: CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (219) — exercise price 3.549
Disposed (D)2190—218Direct (D) No
F2
  • F2 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.
Open filing 0001193125-26-303600 Read from the filing’s XML Dispute this row
2026-07-13 Filed 2026-07-14Giordano Christopher Thomas Director · Officer: CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (8,500) — exercise price 5.94
Disposed (D)8,5000—1,241,500Direct (D) No— Open filing 0001193125-26-303600 Read from the filing’s XML Dispute this row
2026-05-11 Filed 2026-05-13STAAB THOMAS R II Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)10,0000—10,000Direct (D) No
F1
  • F1 Represents a restricted stock award which vests 25% ten days after the grant date, with the remainder vesting in three equal installments on the four-month, eight-month and twelve-month anniversaries of the grant date, subject to the Reporting Person's continued employment.
Open filing 0001193125-26-221926 Read from the filing’s XML Dispute this row
2026-05-11 Filed 2026-05-13STAAB THOMAS R II Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (450,000) — exercise price 11.95
Acquired (A)450,0000—450,000Direct (D) No
F2
  • F2 The options vest and become exercisable as follows: 25% vest on May 11, 2027, and thereafter, the remainder vest in substantially equal installments on each monthly anniversary of the grant date for a period of 36 months, subject to the Reporting Person's continued employment.
Open filing 0001193125-26-221926 Read from the filing’s XML Dispute this row
2026-01-30 Filed 2026-02-03MCGAULEY THOMAS Officer: Interim CFO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (50,000) — exercise price 12.51
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 The options vest and become exercisable with 50% vesting January 30, 2026 and 50% vesting on May 31, 2026, subject to the Reporting Person's continuous service to the Issuer.
Open filing 0001550701-26-000001 Read from the filing’s XML Dispute this row
2026-01-09 Filed 2026-01-13Hunter Robyn Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (30,000) — exercise price 13.3
Acquired (A)30,0000—30,000Direct (D) No— Open filing 0001713932-26-000001 Read from the filing’s XML Dispute this row
2026-01-09 Filed 2026-01-13Rich Stuart Director · Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (250,000) — exercise price 13.3
Acquired (A)250,0000—250,000Direct (D) No
F4
  • F4 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
Open filing 0001841785-26-000001 Read from the filing’s XML Dispute this row
2026-01-09 Filed 2026-01-13Doogan Declan Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (30,000) — exercise price 13.3
Acquired (A)30,0000—30,000Direct (D) No— Open filing 0001704234-26-000001 Read from the filing’s XML Dispute this row
2026-01-09 Filed 2026-01-13Almenoff June Sherie Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (30,000) — exercise price 13.3
Acquired (A)30,0000—30,000Direct (D) No— Open filing 0001492647-26-000001 Read from the filing’s XML Dispute this row
2026-01-09 Filed 2026-01-13Giordano Christopher Thomas Director · Officer: CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (450,000) — exercise price 13.3
Acquired (A)450,0000—450,000Direct (D) No
F1
  • F1 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
Open filing 0001871714-26-000001 Read from the filing’s XML Dispute this row
2026-01-09 Filed 2026-01-13Davidson Michael H. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (30,000) — exercise price 13.3
Acquired (A)30,0000—30,000Direct (D) No— Open filing 0001573785-26-000001 Read from the filing’s XML Dispute this row
2026-01-09 Filed 2026-01-13PROEHL GERALD T Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (30,000) — exercise price 13.3
Acquired (A)3,0000—30,000Direct (D) No— Open filing 0001279191-26-000001 Read from the filing’s XML Dispute this row
2025-12-09 Filed 2025-12-10Rich Stuart Director · Officer: Chief Medical Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)2,50010.2168
25,542

Derived: shares × price per share. Exact value 25542.0000.

5,266Direct (D) No
F3
  • F3 This transaction was executed in multiple trades at prices ranging from $9.70 to $10.45. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Open filing 0001841785-25-000004 Read from the filing’s XML Dispute this row
2025-12-08 Filed 2025-12-10Rich Stuart Director · Officer: Chief Medical Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)2,50010.1002
25,250.5

Derived: shares × price per share. Exact value 25250.5000.

5,000Indirect (I) By Stuart Rich Revocable Trust DTD 11/18/1996No
F1, F2
  • F1 This transaction was executed in multiple trades at prices ranging from $9.76 to $10.42. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
  • F2 The Reporting Person is trustee of the Stuart Rich Revocable Trust DTD 11/18/1996 and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Open filing 0001841785-25-000004 Read from the filing’s XML Dispute this row
2025-12-04 Filed 2025-12-05Rich Stuart Director · Officer: Chief Medical Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)2,5009.1992
22,998

Derived: shares × price per share. Exact value 22998.0000.

2,500Indirect (I) By Stuart Rich Revocable Trust DTD 11/18/1996No
F3, F4
  • F3 This transaction was executed in multiple trades at prices ranging from $9.00 to $9.46. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
  • F4 The Reporting Person is trustee of the Stuart Rich Revocable Trust DTD 11/18/1996 and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Open filing 0001841785-25-000003 Read from the filing’s XML Dispute this row
2025-12-03 Filed 2025-12-05Rich Stuart Director · Officer: Chief Medical Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,5009.0786
13,617.9

Derived: shares × price per share. Exact value 13617.9000.

2,766Direct (D) No
F2
  • F2 This transaction was executed in multiple trades at prices ranging from $8.88 to $9.22. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Open filing 0001841785-25-000003 Read from the filing’s XML Dispute this row
2025-12-02 Filed 2025-12-05Rich Stuart Director · Officer: Chief Medical Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,0009.0059
9,005.9

Derived: shares × price per share. Exact value 9005.9000.

1,266Direct (D) No
F1
  • F1 This transaction was executed in multiple trades at prices ranging from $8.89 to $9.06. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Open filing 0001841785-25-000003 Read from the filing’s XML Dispute this row
2025-11-20 Filed 2025-11-20Giordano Christopher Thomas Director · Officer: CEO
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)5387.5887
4,082.7206

Derived: shares × price per share. Exact value 4082.7206.

2,605Direct (D) No
F3
  • F3 This transaction was executed in multiple trades at prices ranging from $7.54 to $7.73. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Open filing 0001871714-25-000002 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,925 filings read, the latest filed 2026-11-19. Prior quarter ending 2026-06-30: 9,176 filings read.

Showing 1–50 of 124

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
ADAR1 Capital Management, LLC 6,524,151 SH12,330,645 dollarsHigher by 6,303,689 Prior quarter: 220,462Open filing 0001940272-26-000033 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager2,805,496 SH5,302,387 dollarsHigher by 1,077,508 Prior quarter: 1,727,988Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
Vivo Capital, LLC 2,500,000 SH4,725,000 dollarsUnchanged Prior quarter: 2,500,000Open filing 0001213900-26-119459 Filed 2026-11-13 Dispute this row
SPHERA FUNDS MANAGEMENT LTD. Partly reported under another manager2,315,696 SH4,376,665 dollarsHigher by 2,195,496 Prior quarter: 120,200Open filing 0001496201-26-000006 Filed 2026-11-16 Dispute this row
MARSHALL WACE, LLP Partly reported under another manager1,779,564 SH3,363,374 dollarsHigher by 1,193,986 Prior quarter: 585,578Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row
MILLENNIUM MANAGEMENT LLC 1,362,730 SH2,575,560 dollarsHigher by 486,500 Prior quarter: 876,230Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
AQR CAPITAL MANAGEMENT LLC Partly reported under another manager1,252,703 SH2,367,609 dollarsNot in the prior quarter’s filings read Open filing 0001167557-26-000324 Filed 2026-11-16 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 1,131,973 SH2,139,429 dollarsLower by 15,148 Prior quarter: 1,147,121Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
MORGAN STANLEY Partly reported under another manager942,937 SH1,782,152 dollarsHigher by 510,717 Prior quarter: 432,220Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager864,596 SH1,634,455 dollarsHigher by 225,059 Prior quarter: 639,537Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
JANE STREET GROUP, LLC Partly reported under another manager689,312 SH1,302,799 dollarsHigher by 422,656 Prior quarter: 266,656Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager627,023 SH1,185,073 dollarsHigher by 352,077 Prior quarter: 274,946Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
Stonepine Capital Management, LLC 588,000 SH1,111,320 dollarsLower by 72,000 Prior quarter: 660,000Open filing 0001440771-26-000027 Filed 2026-11-13 Dispute this row
BRAIDWELL LP 584,412 SH1,104,539 dollarsUnchanged Prior quarter: 584,412Open filing 0001420506-26-002894 Filed 2026-11-16 Dispute this row
WELLINGTON MANAGEMENT GROUP LLP Partly reported under another manager555,995 SH1,050,830 dollarsHigher by 460,482 Prior quarter: 95,513Open filing 0000902219-26-000323 Filed 2026-11-16 Dispute this row
STATE STREET CORP Partly reported under another manager535,410 SH1,011,925 dollarsHigher by 24,596 Prior quarter: 510,814Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
FMR LLC Partly reported under another manager533,217 SH1,007,780 dollarsLower by 3,409,156 Prior quarter: 3,942,373Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
Caitong International Asset Management Co., Ltd 489,906 SH925,922 dollarsHigher by 489,756 Prior quarter: 150Open filing 0001628280-26-068135 Filed 2026-10-29 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Partly reported under another manager428,063 SH809,039 dollarsHigher by 138,899 Prior quarter: 289,164Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
ADAGE CAPITAL PARTNERS GP, L.L.C. 409,733 SH774,395 dollarsLower by 130,393 Prior quarter: 540,126Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row
Balyasny Asset Management L.P. 369,587 SH698,519 dollarsNot in the prior quarter’s filings read Open filing 0001193125-26-463223 Filed 2026-11-16 Dispute this row
Ikarian Capital, LLC Option: Call 356,600 SH673,974 dollarsLower by 16,500 Prior quarter: 373,100Open filing 0001420506-26-002881 Filed 2026-11-16 Dispute this row
TORONTO DOMINION BANK Option: Call Partly reported under another manager327,000 SH618,030 dollarsNot in the prior quarter’s filings read Open filing 0002052595-26-000123 Filed 2026-11-16 Dispute this row
Caption Management, LLC Option: Call 299,600 SH566,244 dollarsLower by 100,100 Prior quarter: 399,700Open filing 0001706766-26-000008 Filed 2026-11-16 Dispute this row
Qube Research Technologies Ltd 280,621 SH530,374 dollarsLower by 149,272 Prior quarter: 429,893Open filing 0001729829-26-000018 Filed 2026-11-13 Dispute this row
UBS Group AG Partly reported under another manager274,223 SH518,282 dollarsHigher by 176,080 Prior quarter: 98,143Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
PRUDENTIAL FINANCIAL INC Partly reported under another manager249,695 SH471,924 dollarsNot in the prior quarter’s filings read Open filing 0001137774-26-000233 Filed 2026-11-16 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 247,776 SH468,297 dollarsHigher by 78,935 Prior quarter: 168,841Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
Quadrature Capital Ltd Partly reported under another manager238,886 SH451,495 dollarsNot in the prior quarter’s filings read Open filing 0001651424-26-000014 Filed 2026-11-13 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager234,818 SH443,806 dollarsHigher by 35,684 Prior quarter: 199,134Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
Ensign Peak Advisors, Inc 234,205 SH442,647 dollarsHigher by 57,316 Prior quarter: 176,889Open filing 0001454984-26-000011 Filed 2026-11-12 Dispute this row
Nuveen, LLC Partly reported under another manager215,359 SH407,029 dollarsHigher by 54,172 Prior quarter: 161,187Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
VANGUARD FIDUCIARY TRUST CO 212,850 SH402,287 dollarsHigher by 55,808 Prior quarter: 157,042Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
Walleye Capital LLC 204,144 SH385,832 dollarsHigher by 98,907 Prior quarter: 105,237Open filing 0001758720-26-000007 Filed 2026-11-13 Dispute this row
CITIGROUP INC Partly reported under another manager175,348 SH331,407 dollarsHigher by 163,725 Prior quarter: 11,623Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
CITADEL ADVISORS LLC Option: Call Partly reported under another manager167,300 SH316,197 dollarsHigher by 36,900 Prior quarter: 130,400Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Call Partly reported under another manager166,800 SH315,252 dollarsHigher by 70,000 Prior quarter: 96,800Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
JANE STREET GROUP, LLC Option: Call Partly reported under another manager157,500 SH297,675 dollarsHigher by 17,100 Prior quarter: 140,400Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
LMR Partners LLP 150,489 SH284,424 dollarsNot in the prior quarter’s filings read Open filing 0001578621-26-000193 Filed 2026-11-16 Dispute this row
Ikarian Capital, LLC 136,648 SH258,265 dollarsLower by 650,952 Prior quarter: 787,600Open filing 0001420506-26-002881 Filed 2026-11-16 Dispute this row
SPHERA FUNDS MANAGEMENT LTD. Option: Call Partly reported under another manager127,600 SH241,164 dollarsUnchanged Prior quarter: 127,600Open filing 0001496201-26-000006 Filed 2026-11-16 Dispute this row
BARCLAYS PLC Partly reported under another manager124,205 SH234,748 dollarsHigher by 116,151 Prior quarter: 8,054Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
Jones Hill Capital LP 122,169 SH230,899 dollarsNot in the prior quarter’s filings read Open filing 0002102314-26-000006 Filed 2026-11-13 Dispute this row
BOOTHBAY FUND MANAGEMENT, LLC Option: Call 106,100 SH200,529 dollarsLower by 5,000 Prior quarter: 111,100Open filing 0001549230-26-000012 Filed 2026-11-16 Dispute this row
JANE STREET GROUP, LLC Option: Put Partly reported under another manager100,900 SH190,701 dollarsHigher by 85,400 Prior quarter: 15,500Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
Engineers Gate Manager LP 99,996 SH188,992 dollarsNot in the prior quarter’s filings read Open filing 0001620220-26-000010 Filed 2026-11-16 Dispute this row
SIMPLEX TRADING, LLC Option: Call 94,200 SH178,038 dollarsLower by 53,300 Prior quarter: 147,500Open filing 0001488542-26-000013 Filed 2026-11-04 Dispute this row
Caption Management, LLC 93,005 SH175,779 dollarsLower by 161,995 Prior quarter: 255,000Open filing 0001706766-26-000008 Filed 2026-11-16 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 89,743 SH169,614 dollarsHigher by 28,569 Prior quarter: 61,174Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager84,079 SH158,909 dollarsLower by 241,217 Prior quarter: 325,296Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • PERCEPTIVE ADVISORS LLC 1,700,000 SH
  • Candriam S.C.A. 749,588 SH
  • CITADEL ADVISORS LLC 728,561 SH
  • RTW INVESTMENTS, LP 696,570 SH
  • Point72 Asset Management, L.P. 556,761 SH
  • Velan Capital Investment Management LP 549,985 SH
  • Woodline Partners LP 531,254 SH
  • Sofinnova Investments, Inc. 500,039 SH
  • Jupiter Topco LLC 451,226 SH
  • Siren, L.L.C. 427,141 SH
  • Trexquant Investment LP 321,604 SH
  • DIADEMA PARTNERS LP 307,000 SH
  • Logos Global Management LP 300,000 SH
  • Avidity Partners Management LP 265,934 SH
  • Balyasny Asset Management L.P. 194,000 SH
  • ExodusPoint Capital Management, LP 184,501 SH
  • Integral Health Asset Management, LLC 167,000 SH
  • RENAISSANCE TECHNOLOGIES LLC 164,000 SH
  • LANDSCAPE CAPITAL MANAGEMENT, L.L.C. 132,272 SH
  • RAYMOND JAMES FINANCIAL INC 117,482 SH
  • STEMPOINT CAPITAL LP 96,273 SH
  • HRT FINANCIAL LP 85,700 SH
  • TD Asset Management Inc 73,146 SH
  • FRED ALGER MANAGEMENT, LLC 71,967 SH
  • Caption Management, LLC 67,000 SH
  • Sixth Street Partners Management Company, L.P. 61,174 SH
  • Vestal Point Capital, LP 53,439 SH
  • Man Group plc 49,044 SH
  • MANUFACTURERS LIFE INSURANCE COMPANY, THE 47,249 SH
  • Artia Global Partners LP 42,080 SH
  • Quinn Opportunity Partners LLC 40,000 SH
  • FRANKLIN RESOURCES INC 35,267 SH
  • Squarepoint Ops LLC 33,334 SH
  • SummitTX Capital, L.P. 19,993 SH
  • Ikarian Capital, LLC 16,500 SH
  • MetLife Investment Management, LLC 14,940 SH
  • Quantbot Technologies LP 10,735 SH
  • DIVERSIFIED TRUST CO 10,022 SH
  • K2 PRINCIPAL FUND, L.P. 10,000 SH
  • Rosalind Advisors, Inc. 6,200 SH
  • China Universal Asset Management Co., Ltd. 3,600 SH
  • Persistent Asset Partners Ltd 782 SH
  • NISA INVESTMENT ADVISORS, LLC 500 SH
  • Quarry LP 192 SH
  • Commonwealth Retirement Investments LLC 2 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Dellora Investments Master Fund LP Common Stock, $0.0001 par value per share5.52,061,000.0010/02/2026 Filed 2026-10-09SCHEDULE 13G/AAmendment 5Open filing 0001943462-26-000008 Dispute this row
Dellora Investments LP Common Stock, $0.0001 par value per share6.42,400,000.0010/02/2026 Filed 2026-10-09SCHEDULE 13G/AAmendment 5Open filing 0001943462-26-000008 Dispute this row
Kevin Pyun Common Stock, $0.0001 par value per share6.42,400,000.0010/02/2026 Filed 2026-10-09SCHEDULE 13G/AAmendment 5Open filing 0001943462-26-000008 Dispute this row
RTW Investments, LP Common Stock, $0.0001 par value0.00.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0001493215-26-000210 Dispute this row
Roderick Wong Common Stock, $0.0001 par value0.00.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0001493215-26-000210 Dispute this row
BIOTECHNOLOGY VALUE FUND L P Common Stock, $0.0001 par value per share8.23,356,851.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000921895-26-003191 Dispute this row
BVF I GP LLC Common Stock, $0.0001 par value per share8.23,356,851.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000921895-26-003191 Dispute this row
BIOTECHNOLOGY VALUE FUND II LP Common Stock, $0.0001 par value per share2.0769,485.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000921895-26-003191 Dispute this row
BVF II GP LLC Common Stock, $0.0001 par value per share2.0769,485.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000921895-26-003191 Dispute this row
Biotechnology Value Trading Fund OS LP Common Stock, $0.0001 par value per share037.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000921895-26-003191 Dispute this row
BVF Partners OS Ltd. Common Stock, $0.0001 par value per share037.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000921895-26-003191 Dispute this row
BVF GP HOLDINGS LLC Common Stock, $0.0001 par value per share9.934,126,336.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000921895-26-003191 Dispute this row
BVF PARTNERS L P/IL Common Stock, $0.0001 par value per share9.994,150,818.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000921895-26-003191 Dispute this row
BVF INC/IL Common Stock, $0.0001 par value per share9.994,150,818.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000921895-26-003191 Dispute this row
LAMPERT MARK N Common Stock, $0.0001 par value per share9.994,150,818.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000921895-26-003191 Dispute this row
ADAR1 Capital Management, LLC Common Stock, $0.0001 par value per share16.47,447,000.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-128734 Dispute this row
Daniel Schneeberger Common Stock, $0.0001 par value per share16.47,447,000.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-128734 Dispute this row
Vestal Point Capital, LP Common Stock, par value $0.0001 per share00.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0000902664-26-004578 Dispute this row
Ryan Wilder Common Stock, par value $0.0001 per share00.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0000902664-26-004578 Dispute this row
JANUS HENDERSON GROUP Ltd. Common Stock0.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001274173-26-000268 Dispute this row
Sirenia Capital Management LP Common Stock, par value $0.0001 per share5.42,039,069.0009/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0000919574-26-007956 Dispute this row
Alex Silverstein Common Stock, par value $0.0001 per share5.42,039,069.0009/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0000919574-26-007956 Dispute this row
Adage Capital Management, L.P. Common Stock, par value $0.0001 per share2.26857,270.0009/30/2026 Filed 2026-11-12SCHEDULE 13G/AAmendment 2Open filing 0000919574-26-007573 Dispute this row
Robert Atchinson Common Stock, par value $0.0001 per share2.26857,270.0009/30/2026 Filed 2026-11-12SCHEDULE 13G/AAmendment 2Open filing 0000919574-26-007573 Dispute this row
Phillip Gross Common Stock, par value $0.0001 per share2.26857,270.0009/30/2026 Filed 2026-11-12SCHEDULE 13G/AAmendment 2Open filing 0000919574-26-007573 Dispute this row
BlackRock, Inc. Common Stock7.52,804,78809/30/2026 Filed 2026-10-27SCHEDULE 13G/AAmendment 1Open filing 0002012383-26-003851 Dispute this row
Millennium Management LLC Common Stock, par value $0.0001 per share3.61,362,730.0009/30/2026 Filed 2026-10-15SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-116300 Dispute this row
Millennium Group Management LLC Common Stock, par value $0.0001 per share3.61,362,730.0009/30/2026 Filed 2026-10-15SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-116300 Dispute this row
Israel A. Englander Common Stock, par value $0.0001 per share3.61,362,730.0009/30/2026 Filed 2026-10-15SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-116300 Dispute this row
Sphera Funds Management Ltd. Common Stock, par value $0.0001 per share7.092,663,296.0009/30/2026 Filed 2026-10-13SCHEDULE 13G/AAmendment 1Open filing 0001178913-26-004757 Dispute this row
Sphera Global Healthcare GP Ltd. Common Stock, par value $0.0001 per share7.092,663,296.0009/30/2026 Filed 2026-10-13SCHEDULE 13G/AAmendment 1Open filing 0001178913-26-004757 Dispute this row
Sphera Global Healthcare Management LP Common Stock, par value $0.0001 per share7.092,663,296.0009/30/2026 Filed 2026-10-13SCHEDULE 13G/AAmendment 1Open filing 0001178913-26-004757 Dispute this row
ING Groep N.V. Common Stock, $0.0001 par value per share0.00009/03/2026 Filed 2026-09-11SCHEDULE 13G/AAmendment 1Open filing 0001140361-26-036327 Dispute this row
ING Capital Markets LLC Common Stock, $0.0001 par value per share0.00009/03/2026 Filed 2026-09-11SCHEDULE 13G/AAmendment 1Open filing 0001140361-26-036327 Dispute this row
FMR LLC COMMON STOCK1.4514,925.0008/31/2026 Filed 2026-09-08SCHEDULE 13G/AAmendment 1Open filing 0000315066-26-002289 Dispute this row
Abigail P. Johnson COMMON STOCK1.4514,925.0008/31/2026 Filed 2026-09-08SCHEDULE 13G/AAmendment 1Open filing 0000315066-26-002289 Dispute this row
ADAR1 Capital Management, LLC Common Stock, $0.0001 par value per share14.05,257,389.0008/31/2026 Filed 2026-09-08SCHEDULE 13GOpen filing 0001104659-26-105941 Dispute this row
Daniel Schneeberger Common Stock, $0.0001 par value per share14.05,257,389.0008/31/2026 Filed 2026-09-08SCHEDULE 13GOpen filing 0001104659-26-105941 Dispute this row
ING Groep N.V. Common Stock, $0.0001 par value per share7.052,639,66608/19/2026 Filed 2026-08-27SCHEDULE 13GOpen filing 0001140361-26-034749 Dispute this row
ING Capital Markets LLC Common Stock, $0.0001 par value per share7.052,639,66608/19/2026 Filed 2026-08-27SCHEDULE 13GOpen filing 0001140361-26-034749 Dispute this row
Sphera Funds Management Ltd. Common Stock, par value $0.0001 per share5.331,993,496.0008/17/2026 Filed 2026-08-27SCHEDULE 13GOpen filing 0001178913-26-004262 Dispute this row
Sphera Global Healthcare GP Ltd. Common Stock, par value $0.0001 per share5.331,993,496.0008/17/2026 Filed 2026-08-27SCHEDULE 13GOpen filing 0001178913-26-004262 Dispute this row
Sphera Global Healthcare Management LP Common Stock, par value $0.0001 per share5.331,993,496.0008/17/2026 Filed 2026-08-27SCHEDULE 13GOpen filing 0001178913-26-004262 Dispute this row
Millennium Management LLC Common Stock, par value $0.0001 per share5.82,156,891.0008/13/2026 Filed 2026-08-18SCHEDULE 13GOpen filing 0001104659-26-098450 Dispute this row
Millennium Group Management LLC Common Stock, par value $0.0001 per share5.82,156,891.0008/13/2026 Filed 2026-08-18SCHEDULE 13GOpen filing 0001104659-26-098450 Dispute this row
Israel A. Englander Common Stock, par value $0.0001 per share5.82,156,891.0008/13/2026 Filed 2026-08-18SCHEDULE 13GOpen filing 0001104659-26-098450 Dispute this row
Christopher Thomas Giordano Common Stock, $0.0001 par value per share4.321,690,60607/31/2026 Filed 2026-07-31SCHEDULE 13D/AAmendment 1Open filing 0001193125-26-328603 Dispute this row
Vivo Opportunity Fund Holdings, L.P. Common Stock, $0.0001 par value per share9.03,458,327.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-090068 Dispute this row
Vivo Opportunity, LLC Common Stock, $0.0001 par value per share9.03,458,327.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-090068 Dispute this row
Perceptive Advisors LLC Common Stock, $0.0001 par value per share4.51,700,00006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 3Open filing 0001193125-26-352650 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,615,281 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201532,368
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,123

Filings made before the SEC required XML are listed, not extracted.

Back to Tenax Therapeutics, Inc.